Chartwell Investment Partners LLC Invests $662,000 in TransMedics Group, Inc. (NASDAQ:TMDX)

Chartwell Investment Partners LLC acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 4,219 shares of the company’s stock, valued at approximately $662,000.

A number of other hedge funds also recently made changes to their positions in TMDX. BNP Paribas Financial Markets raised its position in TransMedics Group by 35.1% in the 1st quarter. BNP Paribas Financial Markets now owns 17,390 shares of the company’s stock worth $1,286,000 after purchasing an additional 4,518 shares during the period. Russell Investments Group Ltd. raised its position in TransMedics Group by 337,462.5% in the 1st quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock worth $1,997,000 after purchasing an additional 26,997 shares during the period. ProShare Advisors LLC raised its position in TransMedics Group by 7.8% in the 1st quarter. ProShare Advisors LLC now owns 5,871 shares of the company’s stock worth $434,000 after purchasing an additional 427 shares during the period. Entropy Technologies LP purchased a new position in TransMedics Group in the 1st quarter worth $201,000. Finally, State Board of Administration of Florida Retirement System raised its position in TransMedics Group by 8.6% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 9,843 shares of the company’s stock worth $745,000 after purchasing an additional 780 shares during the period. 99.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on TMDX shares. Stephens lifted their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. decreased their price objective on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 29th. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Canaccord Genuity Group decreased their price objective on shares of TransMedics Group from $169.00 to $109.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th. Finally, Robert W. Baird decreased their price objective on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $144.80.

Insider Buying and Selling

In related news, insider Nicholas Corcoran sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the sale, the insider now owns 21,105 shares of the company’s stock, valued at $3,714,902.10. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, insider Nicholas Corcoran sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the sale, the insider now owns 21,105 shares of the company’s stock, valued at $3,714,902.10. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the sale, the director now directly owns 732 shares in the company, valued at $61,158.60. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 36,958 shares of company stock valued at $5,230,528 over the last quarter. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $91.41 on Wednesday. TransMedics Group, Inc. has a 1 year low of $56.83 and a 1 year high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company’s 50-day moving average is $130.45 and its 200 day moving average is $139.89. The stock has a market capitalization of $3.07 billion, a P/E ratio of 97.24 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. During the same quarter in the prior year, the firm earned ($0.12) EPS. TransMedics Group’s quarterly revenue was up 63.7% compared to the same quarter last year. On average, sell-side analysts expect that TransMedics Group, Inc. will post 1.07 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.